U.S. drugmaker AbbVie will develop and commercialize an experimental treatment for inflammatory bowel disease (IBD) from China's FutureGen Biopharmaceutical under a licensing agreement, the compani...

Dividend stocks benefit from falling interest rates as money managers shift to income-oriented equities with yields above the S&P 500.

AbbVie's top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for...

PICCOLO trial met its primary endpoint of objective response rate (ORR) Data from the study will be presented at a future medical meeting NORTH CHICAGO, Ill. , June 6, 2024 /PRNewswire/ -- AbbVie (...

The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that ...

High-yield dividend stocks typically outperform the broader markets over long periods. AbbVie and Pfizer are two attractively priced high-yield dividend stocks worth considering right now.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.

AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i...

AbbVie covers all the bases for investors -- income, value, and growth. AstraZeneca is an inexpensive stock that has solid growth opportunities.

The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ul...

AbbVie, a key player in my dividend growth portfolio, boasts a strong 4% yield and a consistent record of annual hikes. Its robust product lineup and innovative pipeline promise growth. Despite los...

Nvidia's high valuation could make the stock vulnerable to a sell-off if the company fall short of expectations. AbbVie is a top healthcare company with underrated growth prospects.

AbbVie offers a high dividend yield and a great track record of dividend increases. Lowe's Companies is a Dividend King poised to benefit from the aging of U.S. homes.

The "Sell in May and go away" adage suggests selling stocks in May and returning in November, but historical data shows that June and July have been strong months. September is consistently the wor...